Granza Bio
New accelerator entry · 2024-02-28 · the record
In their words
Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity.
What the record says
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Granza Bio
- Source Check — verify what Granza Bio states, against the registers that hold it.
- INVEST — size up this company on the figures its record states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Granza Bio for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Granza BioYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Granza Bio: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. FoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.